Despite the promising avenues of research, there are several barriers. One major challenge is the variability in CGRP levels among individuals, which complicates the establishment of standardized diagnostic markers. Moreover, the high cost of CGRP inhibitors limits their accessibility, raising concerns about health equity. Epidemiologists must also contend with the lack of long-term data on the safety and efficacy of these new treatments.
